
BBNX Stock Forecast & Price Target
BBNX Analyst Ratings
Bulls say
Beta Bionics has demonstrated significant financial growth, with Q3'25 revenue reaching $27.3 million, reflecting a 63.3% year-over-year increase, and notable outperformance against expectations by $3.8 million. The company has revised its revenue forecasts for 2025 and 2026 upward to $97.5 million and $136 million, respectively, bolstered by strong new patient starts, particularly from the pharmacy channel which contributes higher-margin sales. Additionally, the expansion of the insulin pump market through successful conversions of multiple daily injection patients and the increase in sales territories from 43 to 63 further supports a robust outlook for sustained top-line growth in the coming years.
Bears say
Beta Bionics Inc faces several fundamental risks that contribute to a negative outlook for its stock. The company may struggle to achieve significant market share with its iLet product launch amid competitive pressures and complicated pharmacy penetration, which could lead to downward revisions of revenue and profitability estimates. Additionally, challenges in regulatory approvals, potential capital needs resulting in shareholder dilution, and unfavorable changes in Medicare reimbursement frameworks could further hinder the company's financial stability and growth prospects.
This aggregate rating is based on analysts' research of Beta Bionics Inc and is not a guaranteed prediction by Public.com or investment advice.
BBNX Analyst Forecast & Price Prediction
Start investing in BBNX
Order type
Buy in
Order amount
Est. shares
0 shares